Promacta tended to boost platelet counts in patients with low-risk MDS, and helped those patients be independent of transfusions, too. Promacta (eltrombopag) improved platelet counts in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback